Albion Ventures et al. sell Haemostatix to Ergomed

All investors, including Catapult Ventures, Esperante, Nesta and the Wellcome Trust, have exited their shares. Ergomed wholly acquired Haemostatix for an initial consideration of £8m and a contingent consideration of a further £20m.

Ergomed acquired the business as an extension of its co-development portfolio.

Previous funding
In April 2008, Spark Ventures, Catapult and Nesta invested £1.24m in Haemostatix. In 2006, the investors injected a further £3.1m into the company.

Company
Founded in 2003 as a spinout of the University of Leicester and based in Notthingham, Haemostatix develops topical clotting agents. Its technology is based on a novel class of molecule that binds directly to fibrinogen to promote haemostasis and is targeted at the global surgical bleeding market.

People
Albion Venures – Christoph Ruedig (partner).
Ergomed – Miroslav Reljanovic (CEO).

Advisers
Company – JSB Partners (corporate finance).

• Tweet  
• Facebook  
• LinkedIn  
• Google plus  
• Send to  

• Topics
• Exits
• UK / Ireland
• Healthcare
• United Kingdom
• Venture
• Albion Ventures
• Trade sale